Dig Dis Sci: Brass yeast combined with methotrexazole is effective in treating SIBO in patients with systemic sclerosis

Up to 60% of patients with systemic sclerosis (SSc) have small intestine bacterial overgrowth (SIBO), which improves after antibiotic use.
addition, adding probiotics can lead to better results.
a clinical trial evaluated Brass Yeast (SB) VS. Methyl Nitrosazole (M) VS. The results of the study, published online in Dig Dis Sci, reduce gastrointestinal symptoms and the efficacy and safety of SIBO in SSc for 2 months.
study included 40 SIBO and SSc (ACR-EULAR 2013) patients and assigned three groups: M, SB, and M-SB for a period of 2 months.
used a hydrogen exhalation test to measure a few parts per million of hydrogen to evaluate SIBO.
gastrointestinal symptoms using the Results Measurement Information System (NIH-PROMIS) questionnaire reported by patients at the National Institutes of Health.
results show that the baseline characteristics between groups are similar.
age was 53.2±9.3 years, and the evolution of SSc was 13.5 (1-34) years.
2 months of treatment, 55% of SIBO in the M-SB group was eradicated.
diarrhea, abdominal pain, bloating/bloating decreased in the SB and M-SB groups, but the M group remained unchanged.
reduction in hydrogen emissions between 45 and 60min is as follows: in the first and second months, M-SB is 48% and 44%, M is 18% and 20%, and SB is 53% and 60% (P<0.01).
adverse reactions, M (53%) and M-SB (36%) experienced upper abdominal fever and constipation, and SB (22%) experienced bloating/diarrhea.
, the results show that the treatment of methazole is effective for siBO, but the single or combined use of Brass yeast can improve the gastrointestinal outcomes of SSc.
。